Clinical Trial Update: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating irinotecan and cetuximab with or without bevacizumab in metastatic colorectal cancer that progressed after first-line therapy; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• ERBITUX (cetuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 3 | Status: TERMINATED | Results posted: 2014-01-15